Moderna’s COVID-19 Vaccine Gets Fast Track Designation
The FDA has granted Fast Track designation to the vaccine candidate, mRNA-1273 (Moderna), against the novel coronavirus (SARS-CoV-2).
Immunization
AAP: Declines in Immunization During COVID-19 Pandemic Concerning
The AAP has issued a statement regarding recent data published by the Centers for Disease Control and Prevention (CDC) about a decline in pediatric vaccination during the COVID-19 pandemic.
FDA Approves Quadrivalent Meningococcal Vaccine MenQuadfi
The FDA has approved MenQuadfiTM Meningococcal (Groups A, C, Y, W; Sanofi Pasteur) Conjugate Vaccine for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in patients aged ≥2 years.
Pipeline: Investigational Therapies for COVID-19
Currently, there are no antivirals licensed by the FDA to treat patients with COVID-19.
ACIP: 2020 Child and Adolescent Immunization Schedule Updates
The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has released an updated version of the child and adolescent immunization schedule for ages 18 years and younger in the United States.
ACIP: 2020 Adult Immunization Schedule Updates
The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has released an updated version of the adult immunization schedule for ages 19 years and older in the United States.
First Ebola Vaccine Receives FDA Approval
The FDA has approved Ervebo (Ebola Zaire vaccine, live) for the prevention of disease caused by Zaire ebolavirus in individuals ≥18 years of age.
HBV Revaccination Strategies Evaluated in IBD Patients After Initial Vaccination Failure
According to the results of a recent study, an aggressive revaccination strategy involving 3 additional hepatitis B (HBV) vaccine doses is recommended for inflammatory bowel disease (IBD) patients with initial HBV vaccination failure.
Experimental ‘Universal’ Influenza Vaccine Being Evaluated in Healthy Volunteers
The National Institutes of Health has announced the initiation of a phase 1 clinical trial assessing the safety, tolerability, and efficacy of a “universal” influenza vaccine candidate, H1ssF_3928, in healthy adult patients.
Universal Purchase Programs in the United States May Not Effectively Increase Vaccination Rates
Using state- and individual-level data from the 1995-2014 National Immunization Survey, the effect of a state’s Universal Purchase adoption on vaccination rates was estimated.
Next post in Vaccine Information Center
